NCT05249712View on ClinicalTrials.gov

Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2023

Study Completion Date

December 1, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Darolutamide 300 mg

600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.

OTHER

Androgen deprivation therapy

The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.

Trial Locations (1)

Unknown

RECRUITING

Hongqian Guo, Nanning

All Listed Sponsors
collaborator

First Affiliated Hospital of Zhejiang University

OTHER

collaborator

The First Affiliated Hospital of Soochow University

OTHER

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER